Login to Your Account

No Surprises in Genzyme's Trial of Oral MS Drug Aubagio

By Cormac Sheridan
Staff Writer

Wednesday, June 6, 2012
Genzyme Corp.'s once-daily oral multiple sclerosis drug Aubagio (teriflunomide) hit the two main clinical endpoints in a confirmatory pivotal Phase III trial: an annualized reduction in relapse rate and a reduction in the risk of sustained accumulation of disability.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription